Unilife is a U.S. based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for our products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. All of our syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. We are ISO 13485 certified and have FDA-registered medical device manufacturing facilities in Pennsylvania. Our main product is the UnifillTM ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with their injectable drugs and vaccines. We have a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill syringe and is funding our industrialization program. In addition, we have retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.
Unilife to be the sole provider of wearable injectors for all of Sanofi’s applicable large dose volume drugs Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer and supplier of injectable drug delivery systems, announced today the signing of...
Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS), today announced that its Chairman and CEO, Alan Shortall will present at the Leerink Swann Global Healthcare Conference in New York at 1:50 p.m. EST on Thursday, February 13, 2014...
Unilife Corporation (UNIS) To Announce Financial Results For Fiscal Year 2014 Second Quarter On Monday,February 3, 2014
Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS; ASX: UNS) announced today that it intends to release its financial results for the fiscal 2014 second quarter ended December 31, 2013 after market trading ends on Monday, February 3, 2014. Management...